Mars Plans $34 Million Investment in Four New U.S. Veterinary Hospitals as Part of $1.4 Billion Expansion

Mars plans to invest more than $34 million to open four BluePearl and Banfield veterinary hospitals in 2027, creating up to 195 jobs. The expansion is part of a record $1.4 billion U.S. investment that also includes increased production capacity for TEMPTATIONS cat treats.
Logo provided by MARS
  • Mars plans to invest an estimated $1.4 billion in U.S. manufacturing and operations in 2027, its largest annual investment to date.
  • More than $34 million will support four new veterinary hospitals, including three BluePearl locations and one Banfield location.
  • The new hospitals in Maryland, Texas and North Carolina are expected to create up to 195 jobs.
  • Mars is investing $49 million in its Columbus, Ohio, pet food facility to expand U.S. production of TEMPTATIONS Lickable Treats.
  • The company operates more than 2,000 veterinary clinics and hospitals across the United States and employs approximately 80,000 U.S. associates.
  • Mars reports investing more than $9 billion in U.S. manufacturing and operations since 2017.

Mars, Incorporated has announced plans to invest an estimated $1.4 billion in U.S. manufacturing and operations in 2027, including more than $34 million to expand its veterinary hospital network and additional investments in pet food production.

The planned investment represents the largest single-year capital commitment in the company’s history and builds on more than $9 billion invested in U.S. operations since 2017.

For the animal health industry, the announcement highlights continued expansion of Mars Veterinary Health’s clinical infrastructure alongside investments in the company’s pet care manufacturing capabilities.

Four New Veterinary Hospitals Planned for 2027

Mars plans to open four veterinary hospitals in early 2027 through its BluePearl and Banfield networks. The company expects the facilities to expand access to emergency, specialty and general veterinary services in growing U.S. communities.

The planned locations include:

  • BluePearl Pet Hospital: Ellicott City, Maryland
  • BluePearl Pet Hospital: Austin, Texas
  • BluePearl Pet Hospital: Katy, Texas
  • Banfield Pet Hospital: Wilmington, North Carolina

Together, the four facilities represent an investment exceeding $34 million and are expected to create up to 195 jobs.

According to Mars, the new hospitals will incorporate advanced medical capabilities and support the development of skilled veterinary professionals.

The expansion adds to the company’s existing U.S. veterinary footprint, which includes more than 2,000 clinics and hospitals across its veterinary care networks.

Investment Expands U.S. Pet Treat Manufacturing

Mars is also increasing domestic production capacity for its pet care portfolio.

A $49 million investment in the company’s Columbus, Ohio, wet pet food facility will bring production of TEMPTATIONS Lickable Treats to the United States.

The project includes updated mixing and filling technology and is expected to establish annual production capacity exceeding 400 million pouches.

Mars has invested approximately $162 million in the Columbus facility since 2022.

The expansion reflects the company’s efforts to increase domestic manufacturing capabilities and support demand for its pet care products.

Broader Investment Across U.S. Operations

Beyond veterinary services and pet nutrition, Mars continues to invest in its snacking and food manufacturing businesses.

Recent investments include $60 million to expand Trü Frü manufacturing in Salt Lake City, Utah, and $165 million invested since 2024 in its Waco, Texas, confectionery facility.

The company says these projects are intended to modernize manufacturing operations, improve efficiency and strengthen supply chain capabilities.

“As Mars marks 115 years in business, our commitment to American manufacturing has never been stronger,” said Claus Aagaard, chief financial officer of Mars, Incorporated.

Aagaard noted that 94% of Mars products sold in the United States are manufactured domestically, reflecting the company’s long-term investment in U.S. facilities and employees.

Continued Growth in Veterinary Services and Pet Care

Mars operates a broad animal health portfolio that includes veterinary hospital networks Banfield, BluePearl, VCA and AniCura, as well as Antech veterinary diagnostics and pet nutrition brands including Royal Canin, PEDIGREE and WHISKAS.

The company employs approximately 80,000 associates in the United States across manufacturing facilities, research laboratories, offices and veterinary operations.

Its planned 2027 investments further expand the company’s presence in veterinary services and pet care manufacturing as part of a broader strategy to increase capacity and modernize operations across its U.S. businesses.

Information sourced from Mars, Incorporated’s November 10, 2026, press release.

Never Miss an Animal Health Story

Sign up for free to receive the latest veterinary news, product announcements, and industry developments.